Evidence map›Paper›PMID 40967240›Full record

ReviewJournal of neural engineering2025

Multitarget neurostimulation of the deep brain: clinical opportunities, challenges, and emerging technologies.

Michael J Del Sesto, Serban Negoita, Maria Bruzzone Giraldez, Zachary LaJoie, Khaleda Akhter Sathi, Joshua K Wong, Alik S Widge, Michael S Okun, Adam Khalifa

Abstract readReview
In one paragraph

Review in Journal of neural engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Michael J Del SestoCollege of Medicine, MD PhD Training Program, University of Florida, Gainesville, FL, United States of America.ORCID 0009-0007-5365-2626
Serban NegoitaLillian S Wells Department of Neurosurgery, University of Florida, Gainesville, FL, United States of America.ORCID 0000-0003-2477-0379
Maria Bruzzone GiraldezDepartment of Neurology, University of Florida College of Medicine, Gainesville, FL, United States of America.ORCID 0000-0001-7552-1810
Zachary LaJoieCollege of Medicine, MD PhD Training Program, University of Florida, Gainesville, FL, United States of America.ORCID 0000-0002-5942-9210
Khaleda Akhter SathiElectrical and Computer Engineering Department, University of Florida, Gainesville, FL, United States of America.ORCID 0000-0003-0031-9284
Joshua K WongNorman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL, United States of America.ORCID 0000-0002-4632-3417
Alik S WidgePsychiatry, University of Minnesota, Minneapolis, MN, United States of America.ORCID 0000-0001-8510-341X
Michael S OkunNorman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL, United States of America.ORCID 0000-0002-6247-9358
Adam KhalifaElectrical and Computer Engineering Department, University of Florida, Gainesville, FL, United States of America.ORCID 0000-0002-2956-5596

Funding

Minimally Invasive and Versatile Next-Generation Implantable Medical Devices: A Leap Towards Precision Therapies and MedicineDP2EB037188 · NIBIB · UNIVERSITY OF FLORIDA · PI KHALIFA, ADAM · 2024 to 2024
$1.3M
NIBIB NIH HHS DP2 EB037188
6 · The paper itself

Abstract

Recent computational, pre-clinical, and clinical studies have demonstrated the potential for using neuromodulation through simultaneous targeting of multiple deep brain regions. This approach has already been used for therapeutic and systems neuroscience applications. However, the broad clinical adoption of invasive distributed deep brain interfaces remains in its early stages. This review explores the barriers to implementation by addressing three key questions: do the benefits of implanting multiple electrodes justify the associated risks for specific applications? What is the risk-benefit ratio, and what technological advancements will be necessary to encourage clinical adoption? We also examine next-generation technologies that could enable multi-target brain interfaces, including system-on-chip micro-stimulators as well as nanoparticles. We highlight the role of novel machine learning algorithms in the optimization of stimulation parameters and for the guidance of device placement. Emerging hardware accelerators equipped with on-chip AI have demonstrated functionality that can be used to decode and to classify distributed neuronal data. This advance in hardware accelerators has also contributed to the potential for enhanced closed-loop stimulation control of devices. Despite these advances, significant technological and translational barriers persist, limiting the widespread clinical application of multi-target brain interfaces. This review provides a critical analysis of recent prototypes and novel hardware for use in multi-target systems. We will discuss both clinical and research applications. We will focus on the utilization of multi-site technologies to meet the needs of neurological diseases. We conclude that there exists a critical need for further innovation and integration of multi-site technologies into clinical practice.

Indexed as

BrainBrain-Computer InterfacesDeep Brain StimulationAnimalsElectrodes, ImplantedHumansclosed-loop neuromodulationdistributed neurostimulationedge computingmulti-site neuromodulationmultitarget neuromodulationnetwork-level brain modulationneural interfaces

Identifiers

PMID40967240
PMCPMC12453607

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.